Abstract:Objective: This study aims to evaluate whether cardiovascular health (CVH) plays a similar role in the transition from a healthy state to atherosclerotic cardiovascular disease (ASCVD) and subsequent mortality rates in diabetic patients compared to those without diabetes. It also evaluates the effectiveness of CVH in reducing diabetes-related ASCVD risks and enhancing ASCVD-free life expectancy. Research design and methods: This cohort study included 176,669 adults from the UK Biobank, among whom 10,109 (22.3%) were diagnosed with type 2 diabetes mellitus (T2DM). CVH was assessed using the Life's Essential 8 score, encompassing diet, physical activity, smoking, sleep, BMI, blood lipids, blood glucose, and blood pressure. CVH scores were categorized into low, moderate, and high levels based on their distribution among diabetic patients. The main outcomes were the transitions from no ASCVD to the onset of ASCVD and then to mortality, as well as the ASCVD-free life expectancy. Results: In patients with T2DM, high CVH levels were associated with lower ASCVD risk (HR: 0.55, 95% CI: 0.45-0.68 for women; HR: 0.57, 95% CI: 0.50-0.65 for men) and reduced mortality in those with ASCVD (HR: 0.62, 95% CI: 0.39-0.98 for women; HR: 0.62, 95% CI: 0.48-0.79 for men), compared to the low CVH group. No significant difference in CVH's effect on ASCVD and mortality was observed between diabetic and non-diabetic groups. When compared with non-diabetic individuals, no excess risk was observed in incident ASCVD and post-ASCVD mortality among diabetic patients with high CVH. At the age of 40, women with low CVH were expected to live 38.5 years (38.0-39.1) free from ASCVD, which increased to 42.9 years (42.4-43.5) for those with high CVH, while non-diabetic women were predicted to have an ASCVD-free life expectancy of 44.1 years (43.5-44.6). For men at the age of 40, those with low CVH had an ASCVD-free life expectancy of 32.0 years (31.3-32.6), which rose to 37.9 years (37.4-38.6) with high CVH. Non-diabetic men were expected to live 38.3 years (37.7-39.0) free from ASCVD. Notably, life expectancy with ASCVD did not increase with higher CVH levels in both genders. Conclusions: Our findings suggest that the American Heart Association’s recommendations for promoting CVH, initially designed for the general population, are also beneficial for individuals with T2DM. Adopting these guidelines can help mitigate ASCVD progression and enhance life expectancy in diabetic patients.

Lifetime Risk of Cardiovascular Disease and Life Expectancy with and Without Cardiovascular Disease According to Changes in Metabolic Syndrome Status.

Dynamic Changes of Metabolic Syndrome Alter the Risks of Cardiovascular Diseases and All-Cause Mortality: Evidence From a Prospective Cohort Study

Healthy Lifestyle and the Risk of Metabolic Dysfunction-Associated Fatty Liver Disease: A Large Prospective Cohort Study.

Modification of the all-cause and cardiovascular disease related mortality risk with changes in the metabolic syndrome status: a population-based prospective cohort study in Taiwan

Lifestyle behaviors associated with lower risk of having the metabolic syndrome.

Association between Cumulative Metabolic Risk Exposure and Cardiovascular Disease: A Nationwide Cohort of Over 3.6 Million Young Adults

Abstract 4121568: the Influence of Cardiovascular Health on Atherosclerotic Cardiovascular Disease Progression and Life Expectancy among Individuals with Type 2 Diabetes

Impact of Metabolic Syndrome and It's Components on Prognosis in Patients With Cardiovascular Diseases: A Meta-Analysis

The Metabolic Syndrome Increased Risk of Cardiovascular Events in Chinese--a Community Based Study.

Association of Age of Metabolic Syndrome Onset With Cardiovascular Diseases: The Kailuan Study

Effect of Metabolic Syndrome on Prognosis and Clinical Characteristics of Revascularization in Patients with Coronary Artery Disease.

Ideal Cardiovascular Health Metric and Its Change with Lifetime Risk of Cardiovascular Diseases: A Prospective Cohort Study.

HDL-C, Longitudinal Change and Risk of Mortality in a Chinese Cohort Study.

Individual and Combined Associations of Modifiable Lifestyle and Metabolic Health Status With New-Onset Diabetes and Major Cardiovascular Events: The China Cardiometabolic Disease and Cancer Cohort (4C) Study

The Long-Term Effectiveness of Metabolic Control on Cardiovascular Disease in Patients with Diabetes in a Real-World Health Care Setting - A Prospective Diabetes Management Study.

Association between metabolic syndrome severity score and cardiovascular disease: results from a longitudinal cohort study on Chinese adults

Modifiable risk factors and metabolic health in risk of cardiovascular disease among US adults: A nationwide cross-sectional study

Occurrence of metabolic syndrome in midlife in relation to cardiovascular morbidity and all-cause mortality-lessons from a population-based matched cohort study with 27 years follow-up

Ten-year risk of cardiovascular incidence related to diabetes, prediabetes, and the metabolic syndrome

E0376 Effect of Metabolic Syndrome on Prognosis of Revascularization in Patients with Coronary Artery Disease

Associations of Cardiovascular-Kidney-Metabolic syndrome with premature mortality and life expectancies in US adults: a cohort study